{
    "clinical_study": {
        "@rank": "87284", 
        "arm_group": [
            {
                "arm_group_label": "Granulocyte Colony Stimulating Factor", 
                "arm_group_type": "Active Comparator", 
                "description": "Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "normal saline 0.01 ml/kg/day for 5 days subcutaneously"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor\n      (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients."
        }, 
        "brief_title": "The Effect of GCSF in the Treatment of ALS Patients", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Amyotrophic Lateral Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Amyotrophic Lateral Sclerosis", 
                "Sclerosis", 
                "Motor Neuron Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age between 18 and 85\n\n          -  definite or probable ALS according to revised El Escorial criteria\n\n          -  maximum 2 years from initiation of symptoms to study entry\n\n          -  mild to moderate disability according to revised ALS functional rating scale\n             (ALSFRS-r)\n\n        Exclusion Criteria:\n\n          -  familial ALS\n\n          -  pregnancy or lactation\n\n          -  myeloproliferative or hematologic disorders\n\n          -  active immunological disease\n\n          -  liver or renal or heart disease\n\n          -  HIV positive\n\n          -  significant cognitive disorder\n\n          -  hypersensitivity to GCSF"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825551", 
            "org_study_id": "91-01-54-17265"
        }, 
        "intervention": [
            {
                "arm_group_label": "Granulocyte Colony Stimulating Factor", 
                "intervention_name": "Granulocyte Colony Stimulating Factor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Amyotrophic Lateral Sclerosis", 
            "Granulocyte Colony Stimulating Factor"
        ], 
        "lastchanged_date": "November 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Iranian Neurology Research Center of Tehran University of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Iran: Ethics Committee", 
                "Iran: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "based on revised ALS Functional Rating scale (ALSFRS-r)", 
            "measure": "patient`s function", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825551"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "based on cluster of differentiation 34 (CD34) and white blood cell (WBC) counting", 
                "measure": "mobilizing bone marrow stem cells", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "based on compound muscle action potential (CMAP) measured in nerve conduction study", 
                "measure": "amplitude of compound muscle action potential in ulnar and peroneal nerve", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "based on  Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ40)", 
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "based on Muscle Manual Test (MMT)", 
                "measure": "muscle power", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}